The appeal of light-based killing is that it is fundamentally resistance-free. Antibiotics work by targeting specific biochemical pathways that microbes can mutate around; light works by flooding microbes with reactive oxygen species or heat, physical insults that are far harder to evade. The four modalities in the review differ sharply in how they generate those insults. Photodynamic therapy, or aPDT, relies on a photochemical triad: an exogenous, non-toxic photosensitizer such as methylene blue or toluidine blue, light of a matching wavelength, typically red light between 635 and 660 nanometers, and molecular oxygen. Once applied to the tissue and allowed to incubate for five to ten minutes, the photosensitizer absorbs the light and is promoted to an excited triplet state. From there it can follow two destructive pathways. In the type I pathway, it reacts directly with nearby biomolecules, triggering a cascade of reactive oxygen species including superoxide, hydroxyl radicals, and hydrogen peroxide. In the type II pathway, it transfers energy to ground-state oxygen, converting it into highly reactive singlet oxygen. Bacterial membrane oxidation is the most damaging consequence, ripping apart the structures microbes need to survive.

Antimicrobial blue light takes a different route: instead of applying a chemical sensitizer, it exploits the microbes’ own pigments. Wavelengths between 405 and 470 nanometers excite endogenous chromophores, chiefly protoporphyrin IX, the penultimate precursor in heme synthesis, which absorbs most strongly around 405 to 410 nanometers in its Soret band. This is where the biology of periodontal disease creates a remarkable vulnerability. Anaerobic periodontal pathogens such as Porphyromonas gingivalis cannot synthesize heme from scratch; they must scavenge it from host cells. After extracting the iron, they are left with free protoporphyrin IX, which accumulates on their outer membranes and even gives black-pigmented bacteria their characteristic color. Those pigments make the very bacteria that drive periodontitis intrinsically photosensitive to blue light, and they also explain why these species glow red under violet-blue excitation, a property already used in autofluorescence-based plaque diagnostics. In other words, the same wavelength that reveals the pathogens can kill them.

The third strategy, antimicrobial selective photothermolysis, borrows a concept from dermatology and pushes it deeper. Rather than vaporizing tissue like Er:YAG or carbon dioxide lasers, near-infrared lasers at 810, 980, or 1,064 nanometers operate in a spectral window where human tissue is largely transparent but bacterial porphyrins still absorb. If the pulse is shorter than the target’s thermal relaxation time, heat builds up selectively inside the pathogen, destroying it even when bacteria have invaded host cells. Nd:YAG lasers, with pulses of roughly 100 microseconds and peak powers near 1,000 watts, satisfy both physical requirements, whereas continuous-wave diode lasers heat tissue non-selectively. Modeled kill depths for this approach reach two to three millimeters, dwarfing the 90 to 150 micrometers of effective light penetration for blue light and the roughly 23 micrometers of biofilm kill depth measured for aPDT in vitro. Photothermal therapy, the fourth modality, goes further still: exogenous nanoparticles convert continuous near-infrared irradiation into sustained localized heat, penetrating the extracellular polymeric matrix of biofilms to denature microbial proteins and nucleic acids. Above 50 degrees Celsius microbes are destroyed; below 45 degrees the heat instead modulates immune responses and can promote tissue regeneration, opening a rare combination of antimicrobial and regenerative effects.

So why is the clinic not transformed? The review’s central finding is a persistent gap between killing microbes in the laboratory and improving outcomes in patients. In endodontics, the evidence for aPDT looks spectacular on paper: systematic reviews report bacterial load reductions of 91.3 to 100 percent when photosensitizers are introduced into root canals and activated by lasers. Yet when researchers examined the clinical trials closely, only one of four showed any correlation between bacterial reduction and improved treatment outcomes. The mechanistic explanation is sobering. Enterococcus faecalis, detected in 24 to 77 percent of persistent root canal infections, invades dentinal tubules to depths of several hundred micrometers, while aPDT kills only to about 23 micrometers in biofilm. The smear layer retains photosensitizer, and oxygen, essential to the type II reaction, is depleted inside a sealed canal. Reflecting this mismatch, neither the American Association of Endodontists nor the European Society of Endodontology recommends aPDT for endodontic disinfection.

The periodontal story follows the same pattern. Across a meta-analysis of 26 randomized controlled trials, adding aPDT to scaling and root planing produced statistically significant improvements in probing depth, a mean reduction of 0.37 millimeters, and clinical attachment gain of 0.33 millimeters. But both figures fall well below the thresholds of roughly one millimeter and half a millimeter that clinicians consider meaningful. The 2024 Cochrane review rated the certainty of evidence very low, and the European Federation of Periodontology’s S3 guideline explicitly recommends against routine aPDT for stage I to III periodontitis. A 2025 meta-analysis of 26 trials in peri-implantitis found probing pocket depth reductions of 0.8 to 0.9 millimeters, but with low to moderate certainty and high heterogeneity, and the federation’s 2023 guideline again advises against aPDT for non-surgical peri-implantitis therapy or implant surface decontamination. The physical culprits are familiar: oxygen-dependent chemistry performs poorly in the anaerobic niches of deep periodontal pockets, and the photosensitizer struggles to diffuse into mature biofilm.

Selective photothermolysis fares little better despite its deeper reach. Tested only as pulsed Nd:YAG or continuous-wave diode adjuncts to conventional debridement, it was consistently inferior or equivalent to irrigation or scaling alone, with a 2026 umbrella review of nine systematic reviews rating the evidence low to critically low. Notably, the review authors point out that pooled analyses never report pulse parameters or selectivity endpoints, so those trials effectively tested laser-assisted irrigation rather than true selective photothermolysis. Even Nd:YAG-specific meta-analyses show only modest probing depth reduction without attachment gain, so the disappointing result cannot be blamed on continuous-wave settings alone. Nd:YAG also carries a documented risk of dentinal microcracks, and the review stresses that selectivity, the field’s defining theoretical advantage, has never actually been measured in a clinical setting.

There is one genuine clinical success: oral candidiasis. Three separate meta-analyses, spanning hundreds of denture stomatitis patients, found aPDT superior to nystatin in reducing palatal Candida and equivalent to fluconazole, without inducing the resistance that now complicates antifungal therapy, with fluconazole resistance exceeding 50 percent among oral Candida isolates from ICU patients. Low-cost natural photosensitizers such as riboflavin, curcumin, and hypericin have shown antifungal activity as well. Blue light, meanwhile, has demonstrated striking selectivity in vitro: at 415 nanometers, researchers killed 5.42 log units of Candida albicans while losing only 0.11 log units of keratinocyte viability at the equivalent dose, roughly a 42-fold margin, and 405-nanometer LEDs disinfect dual-species biofilms on denture resin. In periodontal patients, a single clinical trial found that twice-daily 455-nanometer exposure over four days reduced Porphyromonas gingivalis by 25 percent and Prevotella intermedia by 56 percent in plaque. Prototype devices, including 405-nanometer mouthguards and wireless blue-light-emitting zirconia implants, achieved substantial bacterial reductions in proof-of-concept studies, though no systematic review or randomized trial exists yet.

Photothermal therapy remains the least mature but perhaps most intriguing direction. A 2025 scoping review on nanomaterial-based phototherapy for caries found only nine publications, none clinical, yet laboratory results are dramatic: silver-doped Prussian blue hydrogels achieved more than 99 percent antibacterial efficacy with remineralization-promoting effects in rat models, and a thermosensitive injectable hydrogel combining mild 45-degree photothermal treatment with photodynamic action killed periodontal pathogens while inducing new bone formation in rats. For deep caries, aPDT reduced bacteria in five of six reviewed studies but showed no improvement in adhesive bond strength compared with conventional disinfectants, and evidence for blue light on carious dentin is limited to a single non-significant study. The review’s authors describe the entire field as mechanism-rich but outcome-poor. Shallow penetration depths, oxygen dependence in anaerobic niches, and narrow thermal safety margins constrain the physical side; nanoparticle compatibility, clearance, and regulatory status constrain the other. What is needed, they argue, are multi-center trials built on standardized protocols that test the hypothesis that actually matters: whether microbial reduction can be translated into durable clinical benefit. Until then, the pills remain, and light waits in the wings.

Subject of Research: Antimicrobial light-based interventions, including photodynamic therapy, blue light, selective photothermolysis, and photothermal therapy, for managing oral infections

Article Title: Antimicrobial light-based interventions for management of oral infections: a mini review

Article References: Hiltch, G., Steier, L., Rupel, K., Ottaviani, G., & Poli De Figueiredo, J. A. (2026). Antimicrobial light-based interventions for management of oral infections: a mini review. Frontiers in Oral Health, 7, Article 1981642. https://doi.org/10.3389/froh.2026.1981642

Image Credits: AI Generated

DOI: 10.3389/froh.2026.1981642

Keywords: antimicrobial resistance, photodynamic therapy, antimicrobial blue light, selective photothermolysis, photothermal therapy, oral infections, endodontics, periodontitis, peri-implantitis, oral candidiasis, dental caries, biofilm

The biological rationale for this call is straightforward once the mechanics of CAR-T therapy are understood. Before engineered T-cells are infused, patients typically receive lymphodepleting chemotherapy, a regimen designed to suppress their existing immune system so that the infused cells can expand without being rejected. This creates a window of profound immunosuppression, often compounded by severe neutropenia, in which the body’s defenses against bacteria, fungi, and viruses are dramatically weakened. At the same time, many candidates for CAR-T have already been through multiple lines of chemotherapy, which damages the oral mucosa, alters saliva production, and disrupts the delicate microbial ecosystem of the mouth. The result is that even a routine dental infection or an untreated cavity can become a serious systemic threat precisely when the patient is most vulnerable.

The oral cavity is, in fact, one of the most microbiologically dense environments in the human body, harboring hundreds of bacterial species alongside fungi such as Candida albicans. When mucosal barriers break down, as they commonly do during intensive cancer therapy, these microorganisms can translocate into the bloodstream. Recent research on Candida has shown how fungal cells can cross the intestinal epithelial barrier, and the same principle applies to oral tissues. In a patient recovering from lymphodepletion and facing the inflammatory storm of cytokine release syndrome, a dental abscess or fungal overgrowth is not a minor inconvenience; it is a potential source of sepsis, treatment delay, or even failure of the CAR-T product itself. Niscola and Del Principe emphasize that oral infectious complications are among the avoidable hazards that a structured dental evaluation could help prevent.

Evidence supporting this concern is accumulating. A retrospective observational study published in the same journal examined oral manifestations and dental management in patients undergoing CAR-T cell therapy and documented a range of problems, including mucositis, infections, and xerostomia, the distressing dryness of the mouth that follows damage to salivary glands. Related work in patients who have undergone allogeneic hematopoietic stem cell transplantation, a closely related form of cellular therapy, has measured long-term changes in the immunological components of saliva, suggesting that glandular function and mucosal immunity may take months or years to recover, if they recover at all. These findings paint a picture of the mouth as a barometer of systemic vulnerability, one that changes measurably during and after aggressive immunotherapy.

The functional consequences extend beyond infection. New clinical data on swallowing outcomes after CAR-T treatment in patients with non-Hodgkin lymphoma have documented dysphagia, or difficulty swallowing, as a real and underappreciated complication of the therapy pathway. Taste disturbances, or dysgeusia, have also been reported in association with immunotherapy, and recent translational work has explored microbiome-aware nutritional strategies to address them. When eating becomes painful, difficult, or unappetizing, patients lose weight, malnutrition sets in, and recovery slows. Oral health, in other words, is not a cosmetic concern but a determinant of whether a patient can maintain the nutritional and physical resilience needed to weather the acute phase of CAR-T therapy and benefit from it in the long run.

Recognizing these risks, the international supportive care community has begun to respond. In 2025, the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology issued a joint clinical practice statement recommending dental evaluation and management before treatment for hematologic malignancies and before CAR-T cell therapy. The statement, authored by an expert panel including Zadik, Raber-Durlacher, Epstein, and colleagues, essentially formalizes what dental oncologists have long practiced: that patients scheduled for intensive immunotherapy should undergo a thorough oral examination, radiographic assessment, and stabilization of active disease before their immune system is deliberately dismantled. Niscola and Del Principe’s commentary can be read as both an endorsement of that guidance and a call to close the gap between recommendation and routine practice.

What would such integration look like in practice? The authors sketch a pathway that begins at patient selection, when a candidate for CAR-T is first identified. At that point, ideally weeks before lymphodepletion begins, a dentist or oral medicine specialist would assess caries risk, screen for periodontal disease and non-vital teeth, evaluate the condition of dentures and oral prostheses, and treat any source of potential infection. Preventive measures would include professional cleaning, fluoride application, and patient education on meticulous oral hygiene. During the hospital admission for infusion, the focus shifts to monitoring for mucositis, managing xerostomia with salivary substitutes or stimulants, and watching for early signs of oral candidiasis or herpes simplex reactivation. After discharge, follow-up dental visits would track healing, address persistent dry mouth or taste changes, and restore function as immune reconstitution proceeds.

The commentary also situates oral care within the broader architecture of CAR-T supportive management, which has grown increasingly sophisticated around toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity. Guidelines for managing these systemic toxicities are now well established, and the authors suggest that oral supportive care deserves the same systematic attention. They point to their own prior work on mucosal toxicity in hematological malignancies, which reviewed prevention and management strategies across the spectrum of intensive therapies, as part of a growing literature arguing that the mucosal surfaces of the body are a frontline in cancer supportive care. The mouth, being simultaneously a sensory organ, a digestive gateway, and a microbial reservoir, sits at the intersection of several of these concerns.

There are practical challenges to implementing the vision. CAR-T therapy is delivered in a relatively small number of specialized centers, and patients often travel long distances for treatment, which complicates coordination with community dental providers. Many patients arrive with years of neglected dental care, particularly those whose cancer diagnosis interrupted routine checkups, and complete dental rehabilitation can take longer than the clinical window allows. Prioritization therefore becomes essential: treating active infection and removing unstable teeth take precedence over elective work, and the MASCC/ISOO statement offers a framework for triage. The authors argue that embedding a dental assessment checklist into the standard CAR-T workup, much as cardiac and infectious disease evaluations are already routine, would require modest resources but could prevent disproportionate harm.

Ultimately, the message of the commentary is one of integration rather than novelty. CAR-T cell therapy represents one of the most striking achievements of modern medicine, and its expanding applications across hematological malignancies continue to grow, as recent reviews of the field document. But the technology’s promise can only be realized if patients survive and thrive through the treatment window, and that depends on the unglamorous details of supportive care. Oral health, the authors contend, should no longer be an afterthought delegated to chance. By bringing dentists into the multidisciplinary team that plans and delivers CAR-T therapy, centers can reduce infectious complications, preserve nutrition and quality of life, and give patients the best possible chance of enjoying the remissions that this remarkable therapy can deliver.

Subject of Research: Integrating oral health and preventive dental care into CAR-T cell therapy supportive care

Article Title: Integrating oral health and preventive dental care into CAR-T cell therapy

Article References: Niscola, P., & Del Principe, M. I. (2026). Integrating oral health and preventive dental care into CAR-T cell therapy. Supportive Care in Cancer, 34(10), Article 1012. https://doi.org/10.1007/s00520-026-11268-8

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11268-8

Keywords: CAR-T cell therapy, oral health, preventive dental care, supportive care, hematologic malignancies, mucositis, immunosuppression, dysgeusia, dysphagia, oral infections, immunotherapy, MASCC/ISOO guidelines